Patient activation with respect to advanced heart failure therapy in patients over age 65 years

Sandra A Carey1, Kristen M Tecson2, Kyle Bass3

  • 1Center for Advanced Heart and Lung Disease, Baylor University Medical Center, 3410 Worth Street, Suite 250, Dallas, TX 75246, USA; Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research Institute, 3410 Worth Street, Suite 560, Dallas, TX 75246, USA.

Insights

Patient activation, or self-management ability, is high in elderly patients considered for advanced heart failure (HF) therapies. Age should not be a barrier to receiving advanced HF treatment.

Area of Science:

  • Cardiology
  • Geriatrics
  • Health Psychology

Background:

  • Determining candidacy for advanced heart failure (HF) therapies in elderly patients presents clinical and ethical challenges.
  • Patient 'activation,' defined as engagement and self-management capacity, is a key selection factor.

Purpose of the Study:

  • To examine the influence of age, patient activation, and psychological factors (depression/anxiety) on selection for advanced HF therapy.
  • To assess the impact of these factors on 6-month survival rates in patients considered for therapy.

Main Methods:

  • Consecutive patients referred for advanced HF therapy completed validated measures of patient activation and anxiety/depression.
  • Data were analyzed comparing participants aged ≥65 years versus <65 years, stratified by therapy approval.

Main Results:

  • Of 168 referred patients, 109 were approved for therapy.
  • Patient activation levels were high (88%) and did not differ significantly between age groups, both among approved and non-approved candidates.
  • Activation correlated with anxiety in older, approved participants, but not with depression.

Conclusions:

  • Concerns about reduced self-management capabilities in elderly patients considered for advanced HF therapy may be unfounded.
  • Chronological age alone should not preclude patients from receiving advanced heart failure therapies.
Abstract

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
241
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
713
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
264
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
223
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
259